Integral Diagnostics Ltd
IDX: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|d#^!?@q | LOCK|Yl | LOCK|Fyx&<Wb |
Integral Diagnostics: Margins Expanding to Plan
Integral guided to fiscal 2026 EBITDA margins expanding to 21%, after lifting 150 basis points to 20% last year. This is driven by reiterated total annualized cost savings of AUD 14 million from the acquisition of Capitol Health, ramp up of new sites, and procurement efficiencies. Shares rose 5%.
